Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zai Lab Ltd - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ZLAB
Nasdaq
2834
https://www.zailaboratory.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zai Lab Ltd - ADR
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
- Mar 13th, 2024 11:05 pm
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
- Mar 6th, 2024 9:01 pm
Zai Lab Announces Participation in March Investor Conference
- Mar 6th, 2024 12:30 pm
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 1:51 pm
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
- Feb 27th, 2024 9:38 pm
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
- Feb 27th, 2024 9:05 pm
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
- Jan 25th, 2024 9:15 pm
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
- Jan 10th, 2024 10:12 pm
Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares
- Jan 5th, 2024 12:02 am
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
- Dec 22nd, 2023 5:00 pm
Zai Lab Announces Participation in January Investor Conference
- Dec 19th, 2023 12:30 pm
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
- Dec 13th, 2023 1:53 pm
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
- Dec 13th, 2023 4:10 am
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
- Dec 7th, 2023 5:17 pm
14 Best Short-Term Stocks to Invest In
- Nov 23rd, 2023 2:42 pm
Institutional investors may adopt severe steps after Zai Lab Limited's (NASDAQ:ZLAB) latest 6.3% drop adds to a year losses
- Nov 17th, 2023 10:00 am
Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 7:39 pm
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Nov 7th, 2023 9:05 pm
Zai Lab Announces Participation in November Investor Conferences
- Oct 26th, 2023 11:30 am
Further weakness as Zai Lab (NASDAQ:ZLAB) drops 4.5% this week, taking three-year losses to 72%
- Oct 23rd, 2023 12:57 pm
Scroll